MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

• Status: Completed
• Trial end date: 1993-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Patient has been diagnosed with mild to moderate hypertension

• Patient has no treatment or active medical problem, other than hypertension that might affect the patients blood pressure

Exclusion Criteria:

• Pregnant of lactating female patients

• Secondary hypertension or history of malignant hypertension

• Sitting systolic blood pressure > 210 mmHg

• History of stroke

• History of myocardial infarction with in the past year

• Current of prior history of heart failure

• Known hypersensitivity to losartan

• Obesity

• Patients known to be HIV positive or known to be positive for Hepatitis B

• Absence of one kidney

• Patient is abusing or previously abused alcohol or drugs with in past two years